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Focal chondral lesions of the knee are the most frequent type of trauma in
younger patients and are associated with a high risk of developing early
posttraumatic osteoarthritis. The only current clinical solutions include
microfracture, osteochondral grafting, and autologous chondrocyte
implantation. Cartilage tissue engineering based on biomimetic scaffolds has
become an appealing strategy to repair cartilage defects. Here, a
chondrogenic collagen-chondroitin sulfate scaffold is tested in an orthotopic
Lapine in vivo model to understand the beneficial effects of the
immunomodulatory biomaterial on the full chondral defect. Using a
combination of noninvasive imaging techniques, histological and whole
transcriptome analysis, the scaffolds are shown to enhance the formation of
cartilaginous tissue and suppression of host cartilage degeneration, while
also supporting tissue integration and increased tissue regeneration over a 12
weeks recovery period. The results presented suggest that biomimetic
materials could be a clinical solution for cartilage tissue repair, due to their
ability to modulate the immune environment in favor of regenerative
processes and suppression of cartilage degeneration.
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Focal chondral lesions of the knee are the
most frequent trauma in younger patients[1]
and are associated with a high risk of de-
veloping early posttraumatic osteoarthritis
(OA).[2,3] However, there are limitations on
articular cartilage regeneration due to a
lack of vasculature, lymphatic, and nerve
supply.[4] As a result, stabilization surgery
is required in most clinical cases in order
to relieve the pain associated with the chon-
dral lesion/trauma, as well as to enhance
functional recovery.[5]
Current treatments for articular cartilage
lesions include microfracture, osteochon-
dral grafting, and autologous chondrocyte
implantation (ACI). These techniques how-
ever have several drawbacks. While ACI
has the limitation of site morbidity and
cartilage tissue availability,[6] allografts may
potentially elicit immune responses.[7] In
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addition, chondroplasty involves exposing subchondral bone or
layers of cartilage, and the natural history of progression after
treatment is unknown. Moreover, ACI requires full-thickness car-
tilage at the margins around the defect and prolonged protection
postoperatively is needed to allow for chondrocyte maturation.[8]
Although these techniques assure joint stabilization, more re-
cently it is thought that OA may also develop in joints that
have been successfully stabilized by surgery, that have normal
biomechanics.[8] Since traditional therapies assure pain reduc-
tion but do not truly restore the original cartilage homeostasis,
tissue engineering represents the most promising tool to greatly
improve outcomes following joint lesion development.[9]
There have been a few groups that have explored the use of
immune modulation through tissue engineering.[9,10] However,
it appears that the tissue engineering field has yet to apply these
principles to joint trauma and concurrent OA development. For
instance, OA has traditionally been classified as a noninflamma-
tory disease. However, this view has been recently challenged
as new research suggests the presence of ongoing immune pro-
cesses’ within the OA joint and the synovium.[5,10] Moreover, OA
disease management using anti-inflammatory drugs and corti-
costeroids provides further evidence that there is an inflamma-
tory component to the disease.[11]
Although the goal of tissue engineering has always been
to boost the regeneration process at the site of the cartilage
defect,[12] recent considerations and knowledge related to the in-
flammatory nature of OA, could point towards the development
of new solutions that not only improve the regeneration of lost
tissue but also reduce the likelihood of developing late-onset OA.
In this regard, the pioneering work of the Elisseeff group[13]
has shown the possibility to conjugate a scaffold with an anti-
inflammatory drug in order to reduce the activation of NF-kB and
the subsequent inflammatory cascade. Our group has recently
developed a biomimetic scaffold that we have shown to have not
only anti-inflammatory effects,[14] but also chondrogenic poten-
tial in vitro.[15] These properties are both linked to the specific
composition, architecture, and mechanical features of the scaf-
fold.
Following injury, inflammation occurs at the site of the joint,
and we believe that by tuning the inflammatory reaction, an
immune-modulatory implant can favor cartilage homeostasis.
Most recently we have shown that the chondroitin sulfate (CS)
functionalized collagen scaffolds (CLCS) used in a 3D in vitro
culture model demonstrate the ability to modulate the inflam-
matory cascade while housing both chondrocyte progenitor and
bone marrow-derived mesenchymal stem cells (MSCs).[16] Fol-
lowing these promising results, in this study, we aimed to under-
stand how an immune-modulatory scaffold helps to restore car-
tilage homeostasis after trauma, indicated by articular cartilage
regeneration.
This study aimed to assess the ability of the CLCS to treat
full-thickness chondral defects in vivo. Using a combination
of delayed gadolinium-enhanced MRI of cartilage (dGEMRIC),
CyTOF, total RNA sequencing, and standard histological analy-
sis, we monitored the effect of our CLCS immuno-tuning scaffold
material for cartilage regeneration following defect introduction.
Activated gene expression cascades indicate the potential regula-
tion of transcriptomic networks consistent with modified inflam-
mation, extracellular matrix (ECM)–cell communication, and re-
newed cartilage homeostasis at 12 weeks postimplantation. Our
tissue engineering design displays a new proof of concept to man-
age OA using a scaffold material that is safe for use in humans. If
used clinically, it could provide a regenerative treatment approach
to a disease with limited treatment options.
2. Results
The porous structure of CSCL scaffolds after freeze-drying has
been determined by SEM imaging (Figure S1A, Supporting In-
formation). At lower magnification, the sample structure is com-
posed by interconnected pores with boundaries defined by sheet-
like structure of fibrillar collagen. At higher magnification, it
can be appreciated how the presence of chondroitin sulfate re-
sulted in a fibrous substructure (Figure S1B,C, Supporting In-
formation). FTIR spectra reported in Figure S1D (Supporting
Information) showed the characteristic collagen vibration peaks
like Amide I (1700–1600 cm−1) and amide II (1600–1500 cm−1),
related to the stretching vibration of C═O bonds and to C–N
stretching and N–H bending vibration, respectively. The sam-
ple contained C ═ O, C–N, and N–H bonds. Amide III region
(approximately 1200–1300 cm−1) is related to the C–N and C–C
stretching, N–H bonds, and CH2 wagging from the glycine back-
bone and proline side chain.
Compressive tests were carried out to evaluate the compres-
sive strength and stiffness of the scaffold (Figure S1E, Supporting
Information). The machine was set up with an appropriate load-
ing cells of 10 N, the scaffold placed between two steel plates,
and the force record for 60 s to a strain level of approximately
35%. The results summarized in Figure 1E (Supporting Infor-
mation) show very weak resistance to compression as expected
for spongy scaffolds[17,18] Shear rheometry is currently gaining
interests as a diagnostic tool to quantify the mechanical prop-
erties of soft tissues, since it allows evaluation of entire tissue
volume mechanic instead of just a thin surface layer of cells per-
formed by other techniques like atomic force microscopy.[15] In
this work, we use rheometric analysis to evaluate the mechanical
parameters of the whole CSCL scaffold (Figure 1F, Supporting
Information). The rheometer system was optimized to charac-
terize the elastic, elastoplastic and viscous flow behavior of the
scaffold. Scaffold storage modulus and loss modulus as a func-
tion of frequency at 1 Hz was recorded. CSCL storage modulus
(G′) was 35244 ± 9439.18 kPa and loss modulus (G″) 10728.5 ±
3462.967 kPa, confirming a high elastic behavior of the scaffold
used for this work (G′ ≥ G).
An experimental procedure was performed with the utilization
of the CLCS scaffold implanted into a critical size defect in vivo
model at an orthotopic site in a lapine joint.[19] A pipeline of the
regeneration study is shown in Figure 1A,B. New Zealand rabbits
underwent a surgical procedure to generate a critical size defect at
the trochlear groove of the knee joint. A 5 mm diameter by 1 mm
height CLCS scaffold was implanted at the right leg defect, while
the left knee was left untreated and used as a control defect. The
patella was then reduced and aligned by checking knee joint flex-
ion mechanics, followed by fascial and skin closures performed
using absorbable sutures. Images of the critical defects are shown
in Figure 1C.
All rabbits were processed for post-surgery dGEMRIC MRI in
order to monitor the success of the surgery and create a baseline
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Figure 1. In vivo study design. A) Pipeline of articular cartilage regeneration in vivo. B) Defects were created in the trochlear groove of NZW rabbits and
treated with biomimetic CLCS scaffolds or left untreated. The molecular composition and pathway analysis were evaluated at 7 days, 6 and 12 weeks
respectively to assess inflammation resolution and regeneration. C) Cartilage defect model surgical procedure from left to right top to bottom. Right
and left knee joints opened with lateral incision and manual lateral patellar dislocation followed by knee flexion to expose the femoral condyles. Creation
of the surgical defect 5 mm diameter by 1 mm depth using a surgical drill. Cartilage full-thickness defect. Positioning of the CLCS scaffold in the created
defect without external attachments. Initiation of the manual patella repositioning with the leg in extension, visual inspection of the surgical procedure
after patellar reposition and successive joint flexion and extensions to regain correct mechanics of the join and maintain the CLCS scaffold under the
patella.
Figure 2. dGEMRIC noninvasive analysis. A,B) Empty defect (control) and CLCS scaffold treated representative dGEMRIC MRI images showing gadolin-
ium contrast T1 relaxation times color coded post-surgery and 12 weeks after treatment. C) CLCS treated cartilage T1 relaxation times compared to empty
defect controls at different time points. Results were tested for significance using two-way ANOVA followed by Sidak’s multiple comparisons test between
groups from a minimum of six biological replicates. * was used for p values lower than 0.05.
for the potential repair process. dGEMRIC is a non-invasive tech-
nique that generates cartilage images that can be used as an in-
direct measurement of glycosaminoglycan (GAG) concentration
in the extracellular cartilage matrix.[20] Representative dGEM-
RIC MRI images and post-surgical T1 quantification results are
shown in Figure 2.
The area where the defect was created can be clearly differen-
tiated from the untouched cartilage zone displaying a brighter
color coding (Figure 2A). Right and left knee T1 relaxation time
images were then quantified resulting in 391.45 ± 113.34 s and
458.5 ± 136.37 s, respectively (Figure 2B). Interestingly, CLCS
implanted right knees exhibited a significant increase (1.17 ±
0.35-fold, p < 0.05) in T1 relaxation time in comparison to the
untreated control.
Images and T1 relaxation times were quantified at 1 and 12
weeks postsurgery. CLCS T1 relaxation mapping displayed a
greater area of colored coding and very few purple GAG depleted
areas. In comparison, untreated controls exhibited less stained
areas, showing higher heterogenicity and purple areas related to
poor GAG content (Figure 2A). CLCS exhibited non-significant
differences in T1 relaxation time average at 1 and 12 week post-
surgery respectively (563.58 ± 123.01 s and 538.43 ± 68.24 s) in
comparison to untreated controls. Interestingly, untreated carti-
lage displayed a significant increase (1.46 ± 0.13-fold, p < 0.05)
in T1 relaxation time 1 week postsurgery in comparison to un-
treated postsurgery controls.
In order to corroborate the above data, cells were extracted
from the excised CLCS scaffolds 1 week following implanta-
tion. Total RNA was extracted, and a gene expression pro-
file was performed. The inflammatory pathways induced by
CLCS implanted at damaged cartilage tissue in vivo were
compared to untreated damaged tissue and healthy controls
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Table 1. List of genes found over-expressed and underexpressed among the 84 tested through the RT2 Profiler PCR array rabbit inflammatory cytokines
& receptors in CSCL scaffolds in vivo compared to untreated defect and to healthy articular cartilage 1 week postimplantation.
Symbol Refseq Description Fold Change 95% CI
Differentially expressed genes in CSCL compared to empty defect
CXCR4 XM_002712124 Chemokine (C-X-C motif) receptor 4 2.05 0.02
IL7R XM_002714135 Interleukin 7 receptor 1.91 0.03
ADIPOQ NM_001082222 Adiponectin, C1Q and collagen domain
containing
5.04 0.002
BMP2 NM_001082650 Bone morphogenetic protein 2 -8.59 0.01
OSM XM_008274704 Oncostatin M-like -42.79 0.008
CX3CL1 XM_002711541 Chemokine (C-X3-C motif) ligand 1 -3.75 0.0001
IL23A XM_002711079 Interleukin 23, alpha subunit -1.99 0.03
Differentially expressed genes in CLCS compared to healthy control
IL1A NM_001101684 Interleukin 1, alpha 2.89 0.03
IL1RN NM_001082770 interleukin 1 receptor antagonist 3.53 0.002
MIF XM_002722561 Macrophage migration inhibitory factor 2.02 0.01
IL10RA XM_008249453 Interleukin 10 receptor, alpha-like 2.1 0.001
BMP4 NM_001195723 Bone morphogenetic protein 4 -2.89 0.008
CXCL13 XM_008267697 Chemokine (C-X-C motif) ligand 13 -9.55 0.01
NAMPT XM_002712033 Nicotinamide phosphoribosyltransferase-like -1.73 0.007
IL21 XM_008267970 Interleukin 21-like -21.02 0.04
IL7 XM_008255687 Interleukin 7-like -2.82 0.03
IL22 XM_002711248 Interleukin 22 -9.06 0.03
LEPR XM_008265107 Leptin receptor-like -10.78 0.03
TNFSF10 XM_002716426 Tumor necrosis factor (ligand) superfamily,
member 10-like
-2.19 0.01
SPP1 NM_001082194 Secreted phosphoprotein 1 -5.05 0.02
through an inflammatory cytokines and receptors PCR array[21]
(Table 1).
Seven genes were found to be differentially expressed in CLCS
treated explants in comparison to damaged untreated cartilage.
The anti-inflammatory adipokine ADIPOQ and chemokine re-
ceptors CXCR4 and IL7R, as well as the anti-inflammatory pro-
teins IL1RA and IL10, were significantly up regulated (p = 0.002
and p = 0.001 respectively). Pro-inflammatory cytokines IL23A,
CX3CL1, BMP2 and OSM and signaling molecules CXCL13, IL7,
IL21, IL22, TNFSF10, SPP1 and LEPR were found downregu-
lated compared to the healthy control.
Volcano scatter and heatmap plots of differentially expressed
genes between in vivo explants are shown in Figure 3. Volcano
plots display the p values in the vertical axis over the fold change
expression in the horizontal axis. ADIPOQ was the most sig-
nificantly overexpressed gene in CLCS treated cartilage com-
pared to untreated, damaged control (Figure 3A). IL1RN and
IL10RA displayed the highest level of significantly increased ex-
pression when compared to healthy cartilage control (Figure 3B).
On the opposite site, IL21 expression displayed the most signif-
icant decrease in expression compared to the healthy controls.
In addition, differentially expressed genes between the CL and
CLCS in vivo explants were clustered in a heatmap of expression
(Figure 3C). Interestingly, RNA expression profiles from CLCS
treated explants clustered together with the healthy control ex-
plants and were opposing to the untreated, damaged cartilage ex-
plants.
To further evaluate the tissue molecular inflammatory re-
sponse induced by CLCS scaffolds implanted at damaged artic-
ular cartilage, the RNA expression was evaluated using specific
gene markers involved in inflammation within the cartilage.[22]
Cytokine expression including TNFa, NOS2, IL1B, IL4, IL6,
CXCL8, and IL10 and cartilage proteases MMP3, MMP13, and
ADAMTS5 specific primers were used to detect the level of ex-
pression in real-time polymerase chain reaction (RT-PCR) exper-
iments (Figure 3D). CLCS treated explants exhibited a significant
decrease (0.18 ± 0.01-fold, p < 0.0001) in TNF𝛼 expression com-
pared to untreated damaged control explants. Similarly, CLCS
treated explants displayed a significant decrease (0.30± 0.01-fold,
p < 0.0001) in NOS2 expression. In addition, CLCS treated ex-
plants inflammatory cytokines IL1B, IL4, and CXCL8 RNA ex-
pression was found downregulated (p < 0.0001) in comparison
to untreated damaged control. However, CLCS treated explants
exhibited a significant increase (7.45 ± 0.34-fold, p < 0.0001) in
IL6 expression compared to untreated damaged control explants
(Figure 3D).
Matrix proteases expression was also compared between
groups. CLCS treated explants displayed a significant decrease
(0.43 ± 0.01-fold, p < 0.05) in ADAMTS5 expression compared to
untreated damaged control. Differently, CLCS treated cartilage
exhibited a significant increase (3.64 ± 0.26-fold and 8.22 ±
0.05-fold, p < 0.05 and p < 0.0001) in MMP13 and MMP3
expression respectively in comparison to untreated controls
1 d postsurgery. Interestingly, CLCS treated cartilage explants
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Figure 3. CLCS implanted scaffolds induction 1 week after surgery.A,B) Scatter volcano plots to visualize differential expression patterns tested through
the RT2 Profiler PCR array rabbit inflammatory cytokines & receptors between CLCS treated and untreated control A) and between CLCS treated and
B) healthy control cartilage. Vertical dotted lines correspond to 1.5-fold up and down respectively, and the horizontal line represents a p value of 0.05.
C) Heatmap of differentially expressed genes between hierarchically clustered CSCL treated, untreated (-CTRL) and healthy cartilage (+CTRL) in in vivo
explants. Differential expression levels of genes are displayed as color-coded: red represents over-expression while green under-expression. D) Inflamma-
tory pathway-specific gene markers relative expression of CLCS treated tissue explants compared to untreated control explants 1-week postimplantation
(healthy control = 1 not shown). Results were tested for significance using two-way ANOVA followed by Sidak’s multiple comparisons test between
groups from a minimum of three biological replicates. * and **** were used for p values lower than 0.05 and 0.0001. E,F) Representative images of
E) hematoxylin and eosin staining of the cellular composition and structure and safranin-O tissue staining F) of ECM composition. All images refer to
untreated empty control (CONTROL) and CLCS scaffold (CLCS) treated joint defects (and insets in red boxes) at 7 d postsurgery. Scale bar represents
1 mm.
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showed a significant increase (2.99 ± 0.40-fold, p < 0.0001) in
anti-inflammatory IL10 expression compared to controls.
In order to determine the tissue level effect of these gene ex-
pression networks, CLCS treated and untreated explants were ex-
amined using H&E and Safranin O staining. H&E stained slides
from 1 week postsurgical CLCS treated samples displayed nu-
clear and ECM staining, indicating the presence of cellular infil-
trates at the damaged area (Figure 3E). The pink-stained porous
collagen-based scaffolds could be delimited from the surround-
ing cartilage tissue. Interestingly, the CLCS scaffolds exhibited
nuclei eosin staining indicating cellular infiltration from the sur-
rounding tissues. In comparison, untreated defects displayed
poor cellular presence (Figure 5E). Safranin O stained slides (Fig-
ure 3F) displayed dark nuclear staining confirming the cellu-
lar infiltration into the porous scaffolds. Moreover, CLCS treated
samples lacked the presence of Safranin O stained areas, show-
ing ECM depletion at the trauma site. The CLCS scaffold may
be expected to stain red in the presence of Safranin O, however
in some instances, monoclonal antibodies are required to stain
proteoglycans following significant depletion.[23] On the contrary,
untreated defects displayed a continuous fade layer of reddish
Safranin O stained area (probably the mineralized cartilage part
remained after the defect) including the presence of round big
cells neighbored close together (Figure 3F).
In order to confirm the data of the RNA array, CyTOFwas used
to evaluate the infiltration of immune cells 1 week postimplanta-
tion. Following implant, the CLCS scaffold has immediate effects
on the type of immune cells that migrate and infiltrate to the site.
Figure 4 demonstrates that among untreated and CLCS samples,
the relative prevalence of immune cells within the knee joint are
significantly different. CLCS samples had a higher proportion of
CD11b+ and CD206 cells, markers that demonstrate immune cells
that are more involved in inflammation resolution. When exam-
ining the cell density of different clusters, there is a statistically
significant difference in a variety of immune cells; CLCS samples
had a statistically higher number of CD3+ (p = 0.03) and CD206+
(p = 0.07) cells, but had a statistically lower number of CD14+ (p
= 0.09), compared to untreated samples (Figure 4B). Moreover,
when all CLCS samples are pooled, the clustering of immune
cells is different compared to untreated samples (Figure 4A). Fig-
ure 4A demonstrates visually that CLCS samples have a smaller
proportion in cluster 2 (CD14+) and cluster 8 (Ki67+).
Finally, in order to monitor the cartilage repair process at
a molecular level, animals were sacrificed, and tissue was
harvested at 12 weeks post surgery; CLCS treated, untreated
and healthy cartilage tissues were then processed for RNA-
sequencing analysis (Figure 5A). Prior to alignment, FastQC was
used to monitor the quality of raw Illumina reads, all of which dis-
played acceptable QC metrics. High-quality reads were unequiv-
ocally aligned to the reference genome, and multiple alignments
were disregarded following recommended ENCODE Guidelines
(Table 2 and Figure 5B).[24]
Sample replicates displayed significant reproducibility in
terms of gene expression, as inferred from the principal compo-
nent analyses (PCA) (Figure 5C). Interestingly, CLCS treated car-
tilage repaired for 12 weeks positioned somewhere in between
both controls, suggesting a more efficient transition towards a
healthy cartilage state (Figure 5C). The sequencing analysis of
the healthy control sample identified 5566 different transcripts,
while 5888 and 5469 transcripts were identified in the untreated
and CLCS samples respectively (Figure 5D). Overall, transcript
expression levels seemed consistent among specimens, however
the untreated sample showed a modest increase in the percent-
age of unique transcripts as opposed to control in comparison
with the CLCS sample (17.1% > 13.7%, Figure 6D). These differ-
ences may account for increased transcriptional activity related
to continuous wound healing.
In order to investigate the level of differential expression be-
tween samples (false discovery rate (FDR)<0.05), both untreated
and CLCS expression profiles were compared to healthy cartilage
using the DESeq2 software package. Results of differential gene
expression analysis between healthy control and untreated sam-
ples pinpointed 293 genes with significantly different levels of
expression (Figure 6A); 169 upregulated and 124 downregulated
(Table S3, Supporting Information). Similarly, 198 genes signifi-
cantly changed their expression levels when evaluating the differ-
ential expression levels of healthy control and CLCS samples (Fig-
ure 6A); 125 and 73 genes with up-regulated and down-regulated
expression respectively (Table S3, Supporting Information). The
list of top differentially expressed genes is depicted in Figure 6B
and includes well-known markers of tissue remodeling and extra-
cellular matrix organization such as MMP13 and COL1A2 (Fig-
ure 6B).
To gain insight into which processes or pathways were signif-
icantly enriched within the list of differentially expressed tran-
scripts, we performed overrepresentation and enrichment tests
using the evolutionary relationship platform PANTHER. Inter-
estingly, overrepresentation analyses on the genes differentially
expressed in the untreated sample compared to control identi-
fied a series of enriched pathways that include processes such as
“Regulation of tissue remodeling” or “Ossification” (Figure 6C).
On the other hand, the only pathway that was significantly en-
riched upon cartilage growth on CLCS was “Extracellular struc-
ture organization” (Figure 6C). These results suggest the preva-
lence of remodeling features on the untreated wound at twelve
weeks post-injury, while the addition of CLCS seems to signifi-
cantly abbreviate the duration of recovery. To corroborate the re-
sults observed with over-representation analyses, we performed
gene-set enrichment tests using PANTHER software. These anal-
yses confirmed that processes related with collagen metabolism
and ossification, amongst others, were strongly enriched in the
untreated sample (Figure 6D) but not in the CLCS sample (Fig-
ure 6E).
In order to assess the organism-specific molecular inflamma-
tory response induced by CLCS scaffolds implanted at damaged
articular cartilage, the RNA-seq dataset was interrogated using
Ingenuity Systems and Ingenuity Pathway Analysis (IPA) path-
way databases. A simplified diagram of the IPA “Inflammatory
pathway” displaying the differential expression of relevant in-
flammatory proteins and their specific receptors is shown in
Figure S4 (Supporting Information). Regardless of the presence
of CLCS scaffolds, cartilage injury seemed to elicit similar
inflammatory-related gene responses after injury (Figure 7A).
For instance, extracellular inflammatory signaling molecules
IL21, SEMA3C, and TNIP1 were equally downregulated follow-
ing cartilage injury both in the untreated and the CLCS samples,
as were inflammatory effectors PTGES, ANXA8, and SOD3
(Figure 7A). Interestingly, adipokine receptor STAB1 was found
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Figure 4. Immune cells’ infiltration after 1 week. A) Total data and empty defect (control) and scaffold treated tSNE plots constructed from Cytof imaging
of inflammatory marker stain panels showing color-coded CD marker-based immune cell clusters, 1 week after treatment. B) Cell density values for each
cluster, separated by ilastik and CellProfiler and attributed to the predominant maker. Results were tested for significance using a nonpaired t-Test and
significant differences in cell clusters denoted with an *. In order to determine the immunomodulary effects of CLCS scaffolds following injury, CyTOF
was used to evaluate the infiltration of immune cells 1 week postimplant. Following implant, the CLCS scaffold has immediate effects on the type and
number of immune cells that migrate and infiltrate to the site. Following implantation, sections of the knee joint were obtained and stained with different
antibodies to determine relative prevalence of different cells. Figure 4B demonstrates that among untreated and CLCS samples, the relative prevalence of
immune cells prevalent within the knee joint are different. CLCS samples had a higher proportion of CD11b+ and CD206 cells, markers that demonstrate
immune cells that are more tissue regeneration rather than inflammation. When examining the cell density of different clusters, there is a statistically
significant difference in a variety of immune cells; CLCS samples had a statistically higher number of CD3+ (p = 0.03) and CD206+ (p = 0.07) cells, but
had a statistically lower number of CD14+ (p = 0.09), compared to untreated samples (Figure 4B). Moreover, when all CLCS samples are pooled, the
clustering of immune cells is different compared to untreated samples (Figure 4A). Figure 4A demonstrates visually that CLCS samples have a smaller
proportion in cluster 2 (CD14+) and cluster 8 (Ki67+).
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Figure 5. RNA sequencing 12 weeks postsurgery. A) Study design and pipeline analysis. CLCS scaffolds treated trochlear defects were excised surgically
12 weeks after surgery and compared to untreated defect and healthy cartilage controls. RNA was extracted from tissue samples and sequenced using
Ilumina RNA sequencing technology. Data were aligned to “oryCun2.0” using Bowtie to produce SAM files. Unique alignments were then counted using
eXpress to produce Text files. Using DESeq2, data were normalized prior to calculation of differential gene expression. IPA software was used to annotate
the results obtained. L (left), R (right), QC (quality control). B) Quality control of the alignment to “oryCun2.0” displaying concordant discordant and
multiple alignment percentages. C) PCA plot displaying the similarities correlated to the distances between experimental groups normalized according
to gene expression. D) Venn diagrams showing the overlap between the lists of expressed transcripts in control, untreated, and CLCS cells.
Table 2. RNA sequencing quality control parameters prior to data analysis. The table reports the sequencing data of the experimental samples number of
reads in the right direction, left direction, and paired reads, the % alignment to the reference genome oryCun2a.fa, multiple and discordant alignments.





Paired reads Concordant Discordant Multiple
Control 1 59616857 90.40% 4.90% 89.80% 4.90% 51987157 85.50% 1.90% 4.90%
Control 2 61583331 88.50% 6.50% 87.90% 6.50% 52360874 83.10% 2.30% 6.50%
Control 3 60644061 91.50% 6.90% 90.80% 6.90% 53498659 86.00% 2.50% 6.90%
Untreated 1 70829783 90.90% 5.60% 90.10% 5.60% 62037139 85.60% 2.20% 5.60%
Untreated 2 62623989 91.20% 6.90% 90.20% 6.90% 54847093 85.20% 2.80% 7.00%
Untreated 3 68335605 90.80% 5.50% 89.70% 5.60% 59555514 85.00% 2.40% 5.60%
CLCS 1 59156456 90.20% 5.90% 88.90% 5.90% 51135627 84.50% 2.20% 6.00%
CLCS 2 67797552 90.90% 7.20% 89.70% 7.30% 59146477 85.20% 2.40% 7.30%
CLCS 3 67854294 91.10% 5.10% 90.10% 5.10% 59582743 86.40% 1.60% 5.20%
significantly upregulated only in the presence of CLCS scaffolds
(Figure 7A and Table S3, Supporting Information), suggesting
modest differences between the inflammatory responses of
treated and untreated rabbits.
To further explore the essential role of the molecular interac-
tion between cells and their surrounding ECM in cartilage tissue
homeostasis,[25] IPA “ECM-cell interaction” and “cartilage home-
ostasis” pathways were interrogated (Figures S5 and S6, Sup-
porting Information). Similar to the inflammatory pathways, the
presence of CLCS did not seem to dramatically alter the expres-
sion landscape of injury recovery (Figure 7B). Both CLCS and
untreated cartilage displayed a significant increase in COL1A1,
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Figure 6. Cartilage transcriptome pathway analysis. A) Volcano plots comparing statistical significance against log2 fold change between control and
untreated/CLCS samples. Green color dots represent significantly down-regulated genes (log2FC < = -0.3, FDR < 0.05). Red color dots represent
significantly upregulated genes (logFC > = 0.39, FDR <0.05). B) Top 15 genes altered (up) in untreated/CLCS cells compared with the control. C) Table
containing the list of PANTHER pathways identified as over-represented when comparing the lists of genes expressed in untreated/CLCS samples as
opposed to control (PANTHER Annotation “GO Biological process”). D,E) Cumulative distribution analyses of the differentially expressed genes in
untreated/CLCS cells, the graphs display fold-change distributions of significantly enriched processes.
Figure 7. CLCS Treatment effect on Inflammation, ECM–cell communication, and cartilage homeostasis. A) Heatmap of differentially expressed genes of
the inflammatory, B) ECM–cell communication, and C) cartilage homeostasis pathways between CSCL treated, untreated and healthy cartilage (control)
in in vivo explants. Raw differentially expressed gene counts obtained from eXpress were mapped using heatmapper software[115] and displayed as
color-coded: red represents overexpression while green underexpression.
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Figure 8. CLCS treated cartilage cellular distribution tissue structure and composition 12 weeks postsurgery. A,B) Representative images of hematoxylin
and eosin staining (A) of the cellular composition and structure and safranin-O tissue staining B) of ECM composition. All images refer to untreated
empty control (CONTROL) and CLCS scaffold (CLCS) treated joint defects (and insets in red boxes) at 12 weeks post-surgery. Scale bar represents
1 mm. C,D) ICRS macroscopic and histological scores. Results were tested for significance using nonparametric Mann–Whitney U test from the three
biological replicates and two experimented observers. * was used for p values lower than 0.05.
COL1A2, COL4A1 COL4A2, and COL22A1 compared to healthy
cartilage (Figure 7B). However, some ECM collagenous com-
ponents such as COL11A1 and COL11A2 were only found to
be significantly altered in the untreated sample. Similar differ-
ences can also be observed in the expression levels of important
baseline membrane glycoproteins such as ACAN or FMOD (Fig-
ure 7A), supporting the idea that CLCS helped faster extracellular
reorganization postinjury, especially in their proteoglycan com-
ponents. Interestingly, key regulators of cartilage homeostasis,
SOX9, MTOR, and its indirect inhibitor TSC2, were only found
to be significantly altered in the untreated samples. Similarly,
members of the MAPK, WNT, RUNX2 and NFKB (MAPK4K
and MINK1, FRZB and FRZ9, RUNDC3B, and NFKB1 respec-
tively), indicators of hypertrophic cartilage, were altered only in
untreated samples. Overall, these results suggested a deviation
from tissue regeneration pathway activation and maintenance of
an active inflammatory state in untreated cartilage in comparison
to CLCS samples.
CLCS treated samples macroscopical and histological analysis
was performed at 12-week postsurgery and compared to previ-
ous timepoints (Figure 8 and Figures S7 and S8, Supporting In-
formation). The International Cartilage Repair Society (ICRS) I
scoring system[26] was utilized to evaluate the samples and com-
pared to untreated controls (Figure 8). Macroscopically scored
CLCS treated samples displayed a significant increase in scoring
average both at 6 and 12 weeks in comparison to the previous
timepoint (1.94 ± 0.18-fold and 1.54 ± 0.06-fold, p < 0.01 and p
< 0.001). However, even though CLCS treated samples average
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score at 12 weeks post-treatment (11.67 ± 0.47) was higher than
control (11.11 ± 0.31), this difference was not statistically signif-
icant.
In addition, fixed surgical CLCS treated samples slides stained
in H&E displayed nuclear and ECM staining homogeneous
across the width of the trochlear groove (Figure 8A). CLCS scaf-
folds could not be identified anymore with the tissue showing
integrity throughout the defect. CLCS treated tissue exhibited
the typical columnar chondrocyte organization through the deep
zone of the tissue different from the superficial zone in the higher
magnification inlets. Moreover, a decrease in cellular to matrix ra-
tio was observed when the images were compared to untreated
damaged tissue at 12 weeks postsurgery (Figure 8A). In addition,
untreated cartilage defects displayed a pleiotropic cellular pres-
ence and areas with increased purple nuclear staining.
Safranin O stained slides from CLCS treated samples dis-
played a superficial thin band of blue staining corresponding to
the superficial articular cartilage zone (Figure 8B). CLCS tran-
sitional and deep zones of repaired cartilage exhibited intense
red staining of the GAGs and disappeared below in the calci-
fied and subchondral bone tissues, stained only in blue. Con-
versely, untreated defects displayed a heterogeneous layer of red-
dish Safranin O stained area across the width of the tissue with
greater areas of blue staining compared healthy cartilage (Fig-
ure 8B). Moreover, untreated damaged cartilage exhibited weaker
red-stained areas in comparison to CLCS treated samples and red
staining was observed in subchondral bone.
The cartilage histology slides were scored following Inter-
national Cartilage Repair Society (ICRS) guidelines.[27] CLCS
treated samples 12-weeks post-treatment showed a significant in-
crease (1.72 ± 0.08-fold, p < 0.05) in average score in comparison
to the first-week post-treatment (Figure 9D). Even though CLCS
treated samples histology score averages increased over time (9 ±
2.45, 11.55 ±1.23, and 15.44 ± 0.68), untreated samples displayed
nonsignificant higher score values at earlier timepoints 1 and 6
weeks (9.78 ± 1.13 and 13.67 ± 1.78) and lower score average
at 12 weeks (13.77 ± 1.25) in comparison to CLCS treated sam-
ples, suggesting that the intrinsic repair mechanism of the lapine
model may be not be sufficient at longer term regeneration when
the CLCS scaffolds might be a better treatment option.
3. Discussion
Tuning the inflammatory process following injury is crucial to
establish long-term cartilage homeostasis. Unlike other tissues,
articular cartilage is composed of chondrocytes and a dense ECM
composed by mainly of collagen Type II and GAG. It is difficult
for chondrocytes to migrate the area of injury due to the dense
structure of hyaline cartilage. Moreover, due to the articular car-
tilage having no blood vessels, migration of cells involved in the
regenerative process is more difficult than other tissues. How-
ever, by implanting a scaffold that not only recruits appropriate
cells, but also tunes the inflammatory response, it is possible to
increase the endogenous regenerative capacity of a tissue that is
inherently difficult to regenerate. Moreover, by tuning the inflam-
matory response, the scaffold is able to allow for the site of injury
to overcome the initial acute inflammatory phase, and redirect
resources towards tissue repair stages.[28]
After insult, initial inflammation is normally resolved within
the first week.[29] In this study, dGEMRC and histology results, as
well as RNA levels, suggested an enhancement of the inflamma-
tory resolution as early as 1-week post-implantation. At 1-week
post-surgery, both empty and experimental cartilage increased
their ECM GAG content. It is not unusual during the first week
for ECM to be produced throughout the wound healing cascade
for any healing process. Starting 3 days after injury, ECM deposi-
tion is an essential step in the repair process. However, the most
appropriate inflammatory response would allow for regeneration
and repair without the formation of a scar.[29] Due to this, ECM
production becomes critical to allow for the regeneration process,
while also avoiding chronic inflammation.
Therefore, further histological and molecular experiments
were performed. Repression of TNFa, NOS2, IL21, IL4, IL7 rele-
vant proinflammatory genes, and activation of anti-inflammatory
IL10, CXCR4 gene expression supported the enhanced inflam-
matory resolution. In addition, FBR absence and lack of giant
body cell formation confirmed the immunomodulatory induc-
tion of the CLCS. This supporting molecular data demonstrated
a mechanism for the resolution of the initial inflammation that
aids to drive the regeneration process.
A differential immunomodulatory expression profile was
exhibited by the CLCS treated cartilage compared to un-
treated empty defects. CLCS scaffolds induced a downregu-
lation of proinflammatory cytokines[30–34] and upregulation of
anti-inflammatory IL10 cytokine,[35–37] but also activated IL6,
MMP3, and MMP13 expression as a compensatory effect for the
immunomodulation.[38] These results correlate with the histolog-
ical differences observed in the cellular and ECM composition
between both experimental groups.
Histological results 1 week posttreatment at explanted CLCS
scaffolds displayed greater integration and cellular infiltration
throughout the entire depth of the scaffolds. Moreover, as ex-
pected, CLCS treated samples did not demonstrate any signs of
foreign body reaction.
The advantage of utilizing a biomimetic scaffold similar to the
native tissue composition, as well as the scaffold having porosity
that enhances cell invasion and growth favored the retention of
invading cells during the initial stages of inflammation.[4] The
increased number of mononucleated cells in the CLCS treated
defects compared to the empty scaffolds allowed for superior
inflammatory resolution, observed by the lack of material encap-
sulation or giant body cells, as well as the molecular analysis.
Both histology and molecular results suggest that CSCL is able to
tune the environment where is placed, favoring a faster inflam-
mation resolution. On the contrary, untreated samples showed
thinner necrotic areas without the presence of cells or clonal
activity at the apical side of the tissue, probably arriving from the
bone marrow. Moreover, big rounded cells were present, which
are indicative of hypertrophy and future apoptosis due to car-
tilage degeneration.[39] This unresolved inflammatory process,
further enhanced by necrosis, released additional alarms to feed
back into the inflammatory process, which can easily lead to
chronic inflammation and cartilage disease. Likewise, Safranin O
staining was chosen to assess the GAG content produced during
the first stages of the cartilage repair process. Bluish-green fast
green staining of collagen from the scaffold further confirmed
the presence and integration of the scaffolds within the native
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tissue. Cartilage matrix deposition and the presence of GAGs
were still reduced at this stage. Conversely, empty defects
showed some staining at the bottom, displaying some hyper-
trophic round chondrocytes under a layer of acellular collagenous
bluish stained matrix, which is indicative of a scar formation
process.[40] These results, not observed in CLCS treated cartilage,
suggest that CLCS scaffolds induced the repression of scar tis-
sue formation. Further development of the scar in the articular
cartilage defect normally evolves into degenerated cartilage or fi-
brocartilage with limited functional capacity and probably results
in further tissue damage, chronic inflammation, and disease.[39]
Cytof analysis showed a snapshot of the infiltrating inflamma-
tory cells at the site of implant at the early time point (1 week
postimplant). Instead of evaluating specific staining, we focused
our attention to identify the overall immune response at the site
of implant. It has been recently reported that type 2 immunity ex-
hibits many host-protective functions, including maintenance of
metabolic homeostasis, suppression of excessive type 1 inflam-
mation, maintenance of barrier defense, and regulation of tis-
sue regeneration.[41] This type of immunity has been described in
multiple different tissues and animal models.[42] The presence of
significantly higher infiltration of CD3+ together with CD4+ (not
significantly higher, but in some samples was found—note out-
liners in Figure 4B) suggests the possibility of activation of type 2
immunity induced by CSCL. Moreover, as recently reported, bio-
logical scaffolds depend on their physicochemical features to pro-
mote the polarization of infiltrating macrophages towards the al-
ternative M2 phenotype.[28] M2 macrophages provide key growth
factors, which aid in wound repair and the promotion of fibro-
genesis. Furthermore, these cells can recruit TH2 effector cells,
which further polarize the response. We found a significant dif-
ference in both CD11b+ and CD206+ cluster (M2 marker), suggest-
ing the high presence of these specific cell types at the site of
implant further confirmed by the overexpression of IL-10 identi-
fied by RNA array and RT-PCR. In fact, M2 macrophages can
dampen the inflammatory response by releasing IL-10, which
can promote regulatory T cell differentiation. Overall, the type
2 response is complex, targeting many cell types and having
both beneficial and pathogenic features that are not mutually ex-
clusive. Moreover, we had several limitations of antibody cross-
reactivity due to the lapine model. However, we were able to con-
firm this unique immune environment and evaluated how this
early response could be translated to a later time point in terms
of tissue homeostasis.
Long-term cartilage tissue regeneration was evaluated 12
weeks postsurgery.[43] Even though complete regeneration was
not achieved at 12 weeks, the results point towards an enhanced
tissue repair process, with cellular and molecular levels indicat-
ing this at the mid-timepoint. Histological and RNA expression
outcomes suggest that the immunomodulatory effect of CLCS
treated insults influenced the repair process and following 12-
weeks of tissue repair, and molecular tools further confirmed the
remodeling of the tissue and reduction of the inflammatory en-
vironment.
Transcriptome analysis allowed for the identification of molec-
ular pathways differentially activated or repressed in response
to immunomodulatory CLCS scaffold treated cartilage com-
pared to untreated cartilage defects.[44,45] Compared to previous
work,[46] differential expression of several members of the TNFa
family TNIP1, TNFRSF1A and TNFRSF11B, NFkB1, MMP9
and MMP13 and interleukins IL21 and IL23A in comparison to
healthy controls was observed.
PCA analysis of the RNA expression data clearly demonstrated
sample replicates in three distinct clusters. Healthy control carti-
lage RNA data clustered at one end of the bidimensional repre-
sentation of the expression, while untreated empty defects RNA
expression data clustered at the opposite side, suggesting that the
homeostatic disruption produced with the insult at surgery was
not restored by intrinsic mechanisms at 12-weeks postsurgery.
Furthermore, the existing differences in gross RNA expression
from CLCS treated cartilage to healthy controls suggest a slower
degree of tissue maturation. Conversely, an intermediary state of
pathway activation is required to regain tissue homeostasis.
Unique signature profiles between untreated and CLCS
treated cartilage was analyzed. As expected, untreated carti-
lage defects displayed a significant downregulation in cartilage-
specific ECM composition and maturation genes such as ACAN,
COL11A1, COL11A2, SOX9.[47] Moreover, inhibition of MTOR
expression, described as a prior step to OA development in a
rat model and associated with OA in humans,[48–50] was found
among the unique repressed genes in untreated empty defect
samples, further confirming a damaged cartilage tissue state.
Additionally, unique expression of biomimetic CLCS scaffolds
treated cartilage defects included several downregulated proin-
flammatory genes such as CD28, ENPP2, and OSMR, coding
for protein activators of the T-cell inflammatory response,[51]
and inflammatory-related cartilage degenerative conditions.[52–54]
IPA was utilized to determine significant cartilage regulatory
pathways within the data sets and to discover any potential reg-
ulatory networks and causal relationships between biomimetic
CLCS treated cartilage immunomodulation and regeneration at
12-weeks postsurgery.
Transcriptome profiling suggests that the immune environ-
ment is being modulated favorably towards a repair process
in CLCS implanted cartilage samples 12 weeks postsurgery.
CLCS scaffold immunomodulatory induction could be observed
when the expression profiles were compared to untreated
cartilage defects. Untreated cartilage displayed a significant
increase in pro-inflammatory IL23 expression observed as
early as 1-week post-surgery. In addition, untreated cartilage
defects exhibited a significant decrease in PTGES, TNIP1, IL21,
semaphorins and annexins RNA expression coding for neces-
sary anti-inflammatory molecules related to TNFa receptors and
NF-kB protein complex,[55] activation of inflammatory condition
through T cells,[56,57] chondrocyte inflammation and osteogenic
differentiation.[58,59] The statistically significant altered expres-
sion in untreated cartilage defects indicates the presence of a
proinflammatory environment within the tissue and lack of
anti-inflammatory capacity to counteract it. Conversely, CLCS
treated cartilage defects did not exhibit significant alterations in
the same mRNA molecules, or they were modulated and less
significant in comparison to the untreated defects. These results
suggest that CLCS scaffolds implanted after cartilage insult,
induced the repression of proinflammatory signals. Many times
this initial inflammatory process is not well resolved, and the
organism may enter into a continuous state of inflammation
becoming a chronic condition and resulting in immature fi-
brotic cartilage tissue.[60,61] However, this chronic inflammatory
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process can easily damage the articular cartilage tissue and
any TE attempt to regenerate the tissue must first suppress
proinflammatory processes in order to produce an environment
that facilitates mature and functional cartilage tissue growth.[62]
The ECM plays a tremendous instructive role, containing cy-
tokines, GFs, and important protein and GAG epitopes that
are recognized by chondrocytes. Upon receiving various signals,
chondrocytes respond accordingly resulting in cellular protein se-
cretion, proliferation, or cell death which affects tissue dynamics
during development, as well as healthy mature function, repair
and disease stages.[63] There were distinct differences in RNA
expression of ECM–cell interaction components between CLCS
and untreated cartilage defects.
Untreated cartilage defects displayed an aberrant of ECM
GAGs and glycoproteins encoding mRNA expression in com-
parison to healthy cartilage. Abnormal expression of important
ECM members such as ACAN, DCN, LUM, FMOD, and NID2
have a direct effect on cartilage composition, transmitted to chon-
drocytes through membrane receptors further signaling through
SOX9 or MAPK, RUN, WNT, and MTOR signaling pathways to
counteract ECM limitations with increased turnover and further
degradation of the cartilage.[64–66]
CLCS scaffold treated cartilage also showed identical expres-
sion of cell adhesion molecules CADM4, SDK2, and NPTN
RNA compared to the healthy control samples, which are all
proteins essential for the selectivity of cellular response to the
environment.[67–72] These results suggest that CLCS treated
cartilage affected the ECM composition by inducing a similar
expression of transmembrane receptors to healthy cartilage,
increasing the chances for restored homeostasis after tissue re-
pair. Integrins, through ligand binding and signal transduction
activation, play an essential role in the cellular interaction with
the surrounding ECM.[60,73] Untreated cartilage defects displayed
a significant decrease in TNS2 and ITGBL1 RNA expression,
whereas biomimetic CLCS scaffold treated cartilage did not
show significant differences in TNS2 expression, even reducing
ITGBL1 expression, suggesting CLCS scaffolds altered cellular
interaction with the surrounding ECM.[74]
Differential gene expression in BMP1, BMP2, and BMP2K
activating the TGFb family and SMAD signaling,[75] FRZB and
FRZ9, related to WNT,[76] LAMTOR1 and MTOR inhibitor cod-
ing gene TSC2,[77] NF-kB1,[78] and MAPK4K and MINK1 from
the MAPK[79] indicated a differential induction of these inflam-
matory signaling pathways in response to CLCS implants in com-
parison to untreated damaged cartilage. In addition, differential
mRNA expression in COL4 and COL11, ACAN and MMP13 was
observed further confirming the scaffolds induction of genes that
are involved in cartilage homeostasis and OA.[80] Moreover, un-
treated empty defects showed increased downregulation in DCN
mRNA expression compared to CLCS treated cartilage. DCN, a
member of the SLRPs, interacts with collagen to organize the
structure of ECM, limits cellular access to proteinases, GFs and
cytokines,[81] and inhibits of the TGFb family and SMAD inflam-
matory signaling pathway, allowing for better wound healing and
regeneration.[82]
MAPK4K and MINK1 expression alterations in untreated carti-
lage defects modulated with biomimetic CLCS scaffold implants
were also revealed. This was confirmed by the dysregulation of
MAPK signaling, a major component of the immune reaction,
inflammatory condition, and cartilage degeneration.[83–86] Excit-
ingly, no significant differences were observed between CLCS
treated defects and healthy cartilage explants in the same MAPK
enzymes, reinforcing the scaffolds immunomodulatory effects at
12 weeks postsurgery.
Untreated damaged cartilage samples displayed a significant
reduction in SOX9 RNA expression, encoding for the cartilage
master regulator protein, possibly linked to SMAD, MAPK/NF-
kB, MTOR, and WNT signaling dysregulation observed in the
same untreated defects. SOX9 dysregulation has catastrophic ef-
fects on cartilage ECM composition, and the negative feedback
loop leads to cartilage disease.[87,88] CLCS treated cartilage did
not show any significant differences in SOX9 expression in com-
parison to healthy cartilage, strongly suggesting a beneficial re-
generative outcome induced by early immune modulation. Im-
portantly, CLCS treated cartilage displayed a significant reduc-
tion in LPR1 mRNA expression indicating a direct relation to
MMP regulation via endocytosis.[89] As a possible consequence
of LPR1 mRNA repression, treated cartilage exhibited a signifi-
cant increase in MMP9 and MMP13 RNA expression, suggesting
that CLCS treated cartilage was still under ECM remodeling, but
not yet in homeostasis compared to healthy cartilage tissue.
The level of regeneration produced over the 12 weeks after
CLCS scaffold implantation was followed via histological and
molecular studies. Overall, a better level of regeneration was
achieved in the CLCS treated cartilage experimental group, dis-
playing tissue organization and composition similar to healthy
tissue, and accompanied by a differential pattern of expression
compared to untreated cartilage, which showed clear histological
and molecular signs of an ongoing inflammatory expression pro-
cess. Although, gross images exhibited a continuous surface in
both experimental groups, rough and irregular areas could be ob-
served on the surface of untreated cartilage, suggesting that the
tissue integrity was not sufficient and probably not responding
properly to the physical demands of the tissue. Gross appearance
is often used to grade the quality of the cartilage and to assess the
level of degeneration whenever invasive techniques with better
resolution are available.[90]
CLCS treated cartilage appeared to have a better continuity
on the surface whereas untreated samples exhibited empty ar-
eas and discontinuous superficial cartilage tissue. In addition,
CLCS treated cartilage displayed a homogenous depth similar
to healthy cartilage that was maintained throughout the entire
width of the insulted area. Conversely, empty defects displayed
thicker areas where bone marrow invasion could be observed
from the subchondral bone and thinner cartilage areas. Differ-
ential cellular composition and organization could also be ob-
served between both groups through the characteristic super-
ficial, middle, deep and calcified zones. CLCS treated samples
displayed flat cellular bodies, which were observed at the sur-
face of the cartilage, while rounder chondrocytes were found in
deeper zones. Moreover, the typical columnar organization of the
cells could be recognized in deeper areas. At high resolution,
CLCS treated cartilage images resembled healthy cartilage ap-
pearance. This was not present in untreated cartilage. The cel-
lular composition was abnormal, without any morphological or
size differences between zones displaying an anisotropic orga-
nization. Hunziker et al. described a similar organization in im-
mature rabbit cartilage.[90] Therefore, it could be inferred that the
Adv. Healthcare Mater. 2021, 2101127 2101127 (13 of 18) © 2021 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advhealthmat.de
biomimetic CLCS scaffolds contributed to a better reorganization
of cells and faster maturation into cartilage tissue that appears
similar to naive healthy tissue.
Regenerated cartilage GAG composition was assessed using
the Safranin O staining. Healthy cartilage is characterized by
increased GAGs content in comparison to other tissues. GAGs
such as ACAN, CS, HS, and DS provide structural and biological
functions required by a very specific and demanding articular car-
tilage tissue.[78] CLCS treated cartilage exhibited a greater and in-
tense brown band indicative of important GAG quantities in the
regenerated tissue. The superficial zone displayed homogeneous
thin band with little or no staining. This is consistent with mature
articular cartilage composition, where GAG content is less abun-
dant in the superficial lamina splendens and increases through-
out the depth of the articular cartilage.[91] Taken together, the his-
tological results showed CLCS treated cartilage defects to be in
a superior regenerative stage at 12 weeks postsurgery. Both the
cellular and ECM components appearance was closer to healthy
cartilage than to untreated cartilage. Biomimetic CLCS scaffolds
induced an immunomodulatory organism reaction during the
initial phase of repair at the tissue, cellular and molecular lev-
els that beneficially affected the repair process during the first 12
weeks of regeneration. However, molecular mechanisms under-
lying cartilage homeostasis and matrix production were analyzed
to confirm the higher quality of the CLCS induced new cartilage.
Not only did the CLCS treated cartilage display superior prop-
erties observed in histology, but the RNA expression processes
ongoing at 12 weeks were better suited for the maintenance of
the tissue homeostasis and long-term regeneration.
The results observed demonstrated physical support and in-
tegration into the tissue allowing for cellular infiltration, tissue
remodeling and regeneration, while also modulating the early
phase inflammatory environment. Excitingly, biomimetic porous
collagen scaffolds functionalized with CS exhibited increased
modulatory capacity against the chronic inflammation produced
after cartilage damage and modulated the inflammatory response
towards an environment of regeneration rather than inflamma-
tion in comparison to untreated controls. This study therefore
demonstrates the utility of biomimetic immunomodulatory 3D
scaffolds for cartilage tissue regeneration in vivo and provides a
platform for further preclinical studies; increasing the study sam-
ple size and utilizing larger mammalian models. Moreover, this
study was performed in a lapine model, and it is well established
that this species has superior cartilage repair properties when
compared to larger animal models (including humans). There-
fore, the results of this study must be confirmed in a model that
has cartilage repair and regeneration abilities more similar to that
of humans prior to translating the use of the CLCS scaffold in the
clinic.
4. Conclusion
The capacity of biomimetic modifications to collagen scaffolds in
the form of CS to modulate the immediate immune environment
and support tissue integration results in increased tissue regen-
eration, which was tested in vivo in an orthotopic lapine model.
The immunomodulatory properties of functionalized CLCS scaf-
folds in vivo were tested at 1 week postsurgery via a comprehen-
sive molecular analysis, as well as through routine histological
and noninvasive cartilage assessment procedures. A whole tran-
scriptome analysis allowed for the understanding of the molec-
ular pathways induced by the CLCS treated cartilage beneficial
for the tissue regeneration after injury and the reduction of the
accompanying chronic inflammatory process leading to disease
states. Last, the porous biomimetic CLCS scaffolds showed im-
proved histological molecular and cellular composition and or-
ganized tissue structure in comparison to untreated controls at 6
and 12 weeks postsurgery. The results presented suggest CLCS
acellular scaffolds can be great candidates for cartilage tissue re-
pair applications due to their ability to modulate the immune en-
vironment in favor of a regenerative process.
5. Experimental Section
Porous Collagen-Chondroitin Sulfate Scaffold Fabrication: CLCS func-
tionalized scaffolds were fabricated from bovine tendon extracted type I
Collagen using a freeze-drying method.[14] 200 g of purchased collagen
type I in acetic acid (5% w/v; Nitta Casings Inc., NJ, USA) were dissolved
in 1 L deionized water at a final concentration of 10 mg mL-1 and mixed
thoroughly. The collagen suspension was then precipitated by the addi-
tion of 0.1 m sodium hydroxide solution until the pH reached 5.5. CS (Car-
bosynth, Berkshire, UK) at a weight molar ratio 10:1 (Collagen:CS) was
added to the solution and thoroughly mixed. 81 μL of 1.5 × 10-3 m BDDGE
were finally added to allow 24 h crosslinking at RT plus another 24 h at
4 °C. After water rinsing, the final slurry was poured onto a 24-well culture
plate and freeze-dried until the resulting porous scaffolds were formed.
The scaffolds were sterilized by UV irradiation for 4 h under a laminar flow
hood.
Scanning Electron Microscopy (SEM): The morphology of the CLCS
scaffold was characterized by scanning electron microscopy (SEM). Scaf-
folds were coated by 7 nm of Pt/Pl for scanning electron microscope (SEM;
Nova NanoSEM 230, FEI, Hillsboro, OR, http://www.fei.com) examina-
tion.
Compression Testing: CSCL scaffolds of 0.5 cm thickness were soaked
in PBS and loaded on UniVert Mechanical Test System. A Load Cell of 10
N was calibrated and used to perform a compression test with a stretch
magnitude of 35% and a stretch duration of 60 s and a relaxation time of
60 s. A minimum of three replicates were performed and recorded for each
condition.
Rheology: Wet scaffolds of 1 mm thickness and 8mm diameter were
analyzed using an Anton Paar/MRC 302 rheometer equipped with an alu-
minum 8 mm insert plate. Both empty scaffolds and cellularized scaffolds
collected at day 7 were characterized. An amplitude sweep test (log ramp
0.001%/10%, angular frequency of 10Hz, 25 recorded points, T of 37 °C)
was used to verify the range of linear viscoelasticity. Frequency response
was measured by frequency sweep tests in the range 1000/0.1 rad s-1
(shear strain of 0.1%, 40 data point, T of 37 °C). Storage modulus and
loss moduli measures were reported as an average of three samples col-
lected at 1 rad s-1 angular frequency.
Fourier Transform Infrared Spectroscopy (FTIR): The samples were an-
alyzed in transmission mode at resolution 4, 64 points, over the range of
500–4000 cm−1 using a Nicolet 6700 spectrometer (Thermo-Fisher Scien-
tific, Waltham, MA, http://www.thermofisher.com). The FTIR spectra were
reported after background subtraction, baseline correction, and reported
on the graph after background subtraction, baseline correction, and nor-
malization on Amide I, within the range of 500–1800 cm−1.
In Vivo Articular Cartilage Rabbit Orthotopic Model: A total of twelve
4 to 5 month old New Zealand white (NZW) rabbits weighting 2 to 3 kg
were selected providing 24 knees for the experimental groups. NZW
underwent a surgical procedure to generate a critical size defect at the
trochlear groove of the knee joint.[92] All procedures followed the IACUC
protocol (IS00004559) established by Houston Methodist Research
Institute’s Institutional Animal Care and Use Committee in accordance
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with the guidelines of the Animal Welfare Act and the Guide for the Care
and Use of Laboratory Animals. Total anesthesia was induced by the CMP
staff using 1–5 mg kg-1 benzodiazepine intramuscularly and maintained
with the continuous administration of inhaled anesthetic isoflurane gas
(1–5%). Following appropriate aseptic procedures, the lateral aspect of
the leg was prepped.
First, a longitudinal skin incision was made directly over the bilateral
knee joints. Arthrotomy was performed via standard medial parapatellar
dissection and the capsule was incised along the medial border of the
quadriceps tendon, patella, and patellar tendon, taking care not to vio-
late the extensor mechanism. Medial soft tissue release, lateral luxation
of the patella, and hyperflexion of the knee were then performed to ex-
pose the weight-bearing surface of the femoral condyles. A full-thickness
osteochondral defect, 4 to 6 mm in diameter by 0.5 to 1 mm in depth, was
created in the trochlear groove using a clinical-grade orthopedic micro-
drill. Both left and right trochleae were insulted, and the use of continuous
saline irrigation helped to remove debris and to reduce heat necrosis to
chondrocytes. A 5 mm diameter by 1 mm height CLCS scaffold was im-
planted at the right leg defect, while the left knee was left untreated and
used as a control defect. Patellar reduction was followed by fascial and skin
closures performed with 2-0 Vicryl and 4-0 Monocryl (Ethicon, NJ, USA)
absorbable sutures respectively.
CMP staff performed the postoperatory care in individual cages of
the animals under CMP standard operating procedures. Analgesics and
antibiotics were administered if indicated by CMP staff, avoiding the
use of carprofen as pain medication due to musculoskeletal healing
interferences.[93] At the end of the experiments, the animals were hu-
manely euthanized by the non-inhalant pharmaceutical method, consist-
ing of 0.22 mg kg-1 administered through the intravenous route.
Delayed Gadolinium-Enhanced Magnetic Resonance Imaging: All rab-
bits were transported under total anesthesia and monitored for immediate
postsurgery (1 week and 12 weeks) dGEMRIC to assess the adequacy
of the tissue deposition and the assessment of repair morphology
process.[94] Omniscan (gadodiamide; GE Healthcare, IL, USA) contrast
agent at 0.2 mL kg-1 (0.1 mmol kg-1) was intramuscularly administered
10 min prior to the imaging procedure. Conventional coronal, radial,
and sagittal MRI imaging at 3 Tesla whole-body MRI scanner (Siemens
MAGNETOM Vida, Siemens Healthineers, Germany) was performed
using a 16-channel transmit-receive knee coil (Philipps Medical Systems
AG, The Netherlands). A standard protocol for dGEMRIC T1 mapping
acquisition was followed and data were processed by the core staff. The
same protocol was followed in both experimental and control knees,
including localizers, as follows. Coronal imaging, 3D T1-weighted turbo
field echo sequence for dGEMRIC (repetition time/echo time 4.6/1.59 ms,
five inversion delays 200-/300-/400-/800-/1200 ms, flip angle 15°, matrix
260 × 198, field of view 13 cm, slice thickness 1.5 mm, bandwidth
478.9 Hz/Px, acquisition time 23:50 min, 79 slices). Radial imaging, 2D
multiecho spin-echo sequences for T2 mapping of cartilage (repetition
time 2000 ms, six echo times 13-/26-/39-/52-/65-/78 ms, flip angle 90°,
matrix 240 × 194, field of view 10 cm, slice thickness 2 mm, bandwidth
291 Hz/Px, acquisition time 16:32 minutes, 30 slices); and a morphologic
radial, 2D proton density-weighted turbo spin-echo sequence without
fat suppression (repetition time/echo time 3085/30 ms, flip angle 90°,
matrix 304 × 299, field of view 7 cm, slice thickness 2 mm, bandwidth
198.6 Hz/Px, acquisition time 9:25 min, 30 slices).
Ex Vivo Histological Staining: At the end of in vivo experiments, tissue
of interest containing the implanted scaffolds was harvested and fixed in
10% NBF overnight. Samples were then transferred to the CMP pathology
department at the HMRI for wax embedding and tissue sectioning. Em-
bedded samples were sectioned to 4 mm using a microtome, flattened in
a 45 °C water bath and immobilized into histology slides. Before stain-
ing, the sections were deparaffinized and hydrated through a series of
successive 10 min incubations. H&E staining following standard stain-
ing protocol using Wiegert’s Iron Hematoxylin solution and 1% Eosin Y
(Sigma-Aldrich, MI, USA) was performed. For Safranin O staining, 0.02%
fast green (Sigma-Aldrich, MI, USA) and 1% Safranin O (Sigma-Aldrich,
MI, USA) were used. After each specific staining protocol, the samples
underwent a dehydration process with 95%, 100% ethanol, and Xylenes.
Finally, mounted glass cover slides (Corning, NY, USA) were imaged using
a an automated Aperio Scanscope AT Turbo Scanner (Leica Biosystems,
IL, USA) with the supporting Aperio ImageScope (Leica Biosystems, IL,
USA) pathology slide viewing software.
Imaging Mass Cytometry/CyTOF Antibody Staining: Metal-labeled an-
tibodies were prepared according to the Fluidigm protocol.[95] Antibodies
were obtained in carrier/protein-free buffer and prepared using the MaxPar
antibody conjugation kit (Fluidigm). After determining the percent yield by
absorbance measurement at 280 nm, the metal-labeled antibodies were di-
luted in Candor PBS Antibody Stabilization solution (Candor Bioscience)
for long-term storage at 4 °C. Antibodies used in this study are listed in Fig-
ure 4.
Samples were baked at 60 °C overnight, then dewaxed in xylene and re-
hydrated in a graded series of alcohol (ethanol absolute, ethanol:deionized
water 90:10, 80:20, 70:30, 50:50, 0:100; 10 min each) for imaging mass cy-
tometry. Heat-induced epitope retrieval was conducted in a water bath at
95 °C in Tris buffer with Tween 20 at pH 9 for 20 min. After immediate
cooling for 20 min, the sections were blocked with 3% bovine serum al-
bumin in tris-buffered saline (TBS) for 1 h. For staining, the sections were
incubated overnight at 4 °C with an antibody master mix (Figure 3E). Sam-
ples were washed four times with TBS/0.1% Tween20. For nuclear stain-
ing, the sections were stained with Cell-ID Intercalator (Fluidigm) for 5
min and washed twice with TBS/0.1% Tween20. Slides were air-dried and
stored at 4 °C for ablation. The sections were ablated with Hyperion (Flu-
idigm) for data acquisition. Imaging mass cytometry data were segmented
by ilastik and CellProfiler. Histology topography cytometry analysis tool-
box (HistoCAT) and R scripts were used to quantify cell number, generate
tSNE plots, and perform neighborhood analysis. For all samples, cellular
densities were averaged across three images per specimen.
Tissue Repair Evaluation: The macroscopic assessment of the repaired
tissue was evaluated using the ICRS I macroscopic scoring system, which
considers the degree of defect repair, the integration to the border zone,
and the macroscopic appearance.[26] Two external observers, both blind
to the treatment, independently scored the specimens.
The histological experimental samples were analyzed at the optical mi-
croscope to evaluate the histological parameters established by the ICRS;
each criterion was evaluated based on the visual analog scale and graded
from 0 to 3.
Gene Expression Analysis: RNA was extracted from snap-frozen har-
vested cartilage tissue samples previously stored at -80 °C. First, a 30 s
homogenization was performed with a PowerGen 125 tissue homogenizer
(ThermoFisher Scientific, MA, USA) in 1 mL of Trizol (Life Technologies,
ThermoFisher Scientific, MA, USA). After homogenization, the samples
were centrifuged at 12 000 g for 10 min at 4 °C and the supernatant was
collected into a new 1.5 mL tube. The samples were thoroughly mixed
with 100 mL chloroform (Sigma-Aldrich, MI, USA) and incubated at RT
for 2 min. A centrifugation cycle for 15 min at 12 000 g and 4 °C was
performed to separate the RNA aqueous phase. RNeasy mini kit (Qiagen,
MD, USA) and its total RNA isolation protocol was applied following
manufacturer’s indications. On-column DNA digestion treatment with
DNAse (Sigma-Aldrich, MI, USA). As a final step, the RNA was eluted in
30 μL of RNase-free water and quantified using a ND1000 spectropho-
tometer (NanoDrop, ThermoFisher Scientific, MA, USA). The cDNA was
synthesized using iScript cDNA synthesis kit (Bio-Rad, CA, USA) from
0.5 mg total RNA at 25 ng μL-1 concentration in the RNA reverse transcrip-
tion master mix. A RNAse-free water (Qiagen, MD, USA) without RNA
sample was included as a negative control to confirm retro-transcription
experimental success. The final mixture was loaded into a CFX96 RT-PCR
detection system thermal cycler machine (Bio-Rad, CA, USA). StepOne
real-time PCR system (Applied Biosystems, ThermoFisher Scientific, MA,
USA) with SYBR green method was used to amplify a specific amount
of cDNA from a target gene that could be detected and quantified
using specific TaqMan target probes (Applied Biosystems, ThermoFisher
Scientific MA, USA). Nonreverse transcribed RNA, RNase-free water, and
reverse transcribed RNase-free water were used as negative controls to
confirm the success of the whole experimental process.[96] The rabbit spe-
cific TaqMan target probes used were: TNFa (Oc03397715_m1), NOS2
(Oc03398289_m1), IL4 (Oc04096359_m1), IL1B (Oc03823250_s1),
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ADAMTS5 (Oc03395870_m1), MMP13 (Oc03396899_m1), IL10
(Oc03396940_m1), MMP3 (Oc03397816_m1), IL6 (Oc03822686_s1),
ACTB (Oc03824857_g1) and GAPDH (Oc03823402_g1)
Inflammatory PCR Array: Rabbit explants RNA extracted 1 week post-
surgery were assessed using Rabbit Inflammatory Chemokines & Recep-
tors RT2 Profiler PCR Array (Qiagen, MD, USA). cDNA synthesis was per-
formed using the RT2 First Strand Kit (Qiagen, MD, USA) from 0.5 μg
total RNA. Before cDNA conversion, genomic elimination buffer (Qiagen,
MD, USA) was used to ensure genomic DNA elimination. Reverse tran-
scription master mix was made adding RT2 First Strand Kit master mix
into the thermal cycler machine, programmed to perform the cDNA con-
version reaction. RT2 SYBR Green RT2 qPCR master mix (Qiagen, MD,
USA) was added to the samples and loaded onto the array plates. ABI 7500
Fast Sequence Detection System (Applied Biosystems, ThermoFisher Sci-
entific, MA, USA) was programmed relative expression was determined
using data from the real-time cycler and the ∆∆CT method. The resulting
Ct values were analyzed through the SABiosciences Web-based PCR Array
Data Analysis Software version 3.5.
RNA Sequencing: Extracted RNA from explanted rabbit articular car-
tilage tissue was totally sequenced and analyzed for in depth molecular
understanding. Only high-quality isolated RNA samples were used in the
downstream analysis, checked using the Agilent 2100 bioanalyzer (Agilent
Inc, CA, USA). High-quality total RNA was then processed for sequenc-
ing library preparation through mRNA selection (polyA tail mediated) and
fragmentation (TruSeq kit protocol). These fragmented mRNA molecules
were converted to cDNA libraries with TruSeq adaptor sequences in or-
der to allow multiple libraries to be run on a single sequencing lane. For
this experiment, the sequencing run was deemed successful after the pro-
prietary quality controls were passed.[97] Base sequence quality scores (Q
scores) threshold was set above Q30. FastQC was used to plot short k-
length nucleotides (k-mer) or single sequences overrepresented at certain
positions in the reads indicating issues at library preparation or library
contamination.[98] All library preparation and sequencing processing was
performed at the Epigenomics Core of Weill Cornell Medical College (New
York, USA).
To analyze RNA sequencing data, an in-house bioinformatics pipeline
was used based on previously published works.[99] A schematic of the
analysis pipeline is provided in Figure 5A. FastQ files that contained
high-quality RNA sequencing reads were aligned to the “oryCun2.0.”[100]
In this process, “Tophat” aligned reads to “oryCun2.0” using the short-
read aligner “Bowtie” prior to identification of splice junctions that lie
between exon regions. Following alignment, “Tophat” produced the re-
quired sequence alignment map (SAM) files required for further analysis
such as, alignment viewing or the identification of differentially expressed
genes.[101] Following alignment to the reference genome, SAM or the bi-
nary version BAM output files were analyzed using “eXpress” software
package to guide downstream specific analysis tasks such as PCA and
identification of differentially expressed genes. The gene count matrix was
used to filter transcripts that were present or absent in each of the experi-
mental conditions; the lists of genes were compared using Venn diagrams
via the InteractiVenn platform.[102]
DEseq2 was then used to calculate differential gene expression be-
tween sample types. In this package for “R” programming environment,
the number of reads per sample was first normalized using an internal
negative binomial model.[103] The significance level of FDR adjusted p-
value of 0.05 was used to identify differentially expressed genes. Raw and
processed RNA-Seq data are deposited in the Gene Expression Omnibus
database with accession number GSE149098.
Finally, the platforms PANTHER and WebGestalt were used to per-
form statistical overrepresentation/enrichment tests.[104,105] All annota-
tion sets were tested for overrepresentation (Binomial test, FDR < 0.05)
comparing the lists of genes expressed in each experimental condition to
those expressed by a standard genome of reference. Similarly, all annota-
tion sets were tested for statistical enrichment using the lists of differen-
tially expressed genes in each experimental condition (FDR <0.05). The
results of statistical enrichment testing are displayed showing the differ-
ential distribution of significantly enriched clusters of genes compared to
the overall expression tendency within samples. IPA software was used for
the interpretation and analysis of the data and elucidate biological inter-
dependencies between differentially expressed genes of the inflammatory,
ECM–cell and cartilage homeostasis customized pathways.[106] Heatmap-
per software[107] was used to display the results as color-coded.
Statistical Analysis: All experimental data distributions were assessed
for normality using the Kolmogorov Smirnov test. For data that did not
follow a normal distribution, a non-parametric Kruskal–Wallis test was ap-
plied to determine significant differences in the median between groups.
A Mann-Whitney U test was then applied ad post hoc to determine signifi-
cant differences between specific group pairs for median scores (IHC) be-
tween, controls versus study groups. Data with a normal distribution, one-
way and two-way Analysis of Variance (ANOVA) tests (GraphPad Prism 6,
CA, USA) followed by Dunnett’s, Tukey ś, or Sidak’s post hoc test, were
used to determine significant differences between groups. The test statis-
tic and corresponding p value were reported, and statistical significance
was defined as p < 0.05. All statistical analysis for each data set described
is listed in the figure legends.
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